307 related articles for article (PubMed ID: 22288823)
1. Increased non-prostate cancer death risk in clinically diagnosed prostate cancer.
van Leeuwen PJ; Otto SJ; Kranse R; Roobol MJ; Bul M; Zhu X; de Koning H; Schröder FH
BJU Int; 2012 Jul; 110(2):188-94. PubMed ID: 22288823
[TBL] [Abstract][Full Text] [Related]
2. Disease-specific survival of men with prostate cancer detected during the screening interval: results of the European randomized study of screening for prostate cancer-Rotterdam after 11 years of follow-up.
Zhu X; van Leeuwen PJ; Bul M; Otto SJ; de Koning HJ; Bangma CH; Schröder FH; Roobol MJ
Eur Urol; 2011 Aug; 60(2):330-6. PubMed ID: 21601352
[TBL] [Abstract][Full Text] [Related]
3. Towards an optimal interval for prostate cancer screening.
van Leeuwen PJ; Roobol MJ; Kranse R; Zappa M; Carlsson S; Bul M; Zhu X; Bangma CH; Schröder FH; Hugosson J
Eur Urol; 2012 Jan; 61(1):171-6. PubMed ID: 21840117
[TBL] [Abstract][Full Text] [Related]
4. Long-term radical prostatectomy outcomes among participants from the European Randomized Study of Screening for Prostate Cancer (ERSPC) Rotterdam.
Loeb S; Zhu X; Schroder FH; Roobol MJ
BJU Int; 2012 Dec; 110(11):1678-83. PubMed ID: 22998182
[TBL] [Abstract][Full Text] [Related]
5. Early detection of high-grade prostate cancer using digital rectal examination (DRE) in men with a prostate-specific antigen level of <2.5 ng/mL and the risk of death.
Hattangadi JA; Chen MH; D'Amico AV
BJU Int; 2012 Dec; 110(11):1636-41. PubMed ID: 22757982
[TBL] [Abstract][Full Text] [Related]
6. Advancing age within established Gleason score categories and the risk of prostate cancer-specific mortality (PCSM).
Russo AL; Chen MH; Aizer AA; Hattangadi JA; D'Amico AV
BJU Int; 2012 Oct; 110(7):973-9. PubMed ID: 22954029
[TBL] [Abstract][Full Text] [Related]
7. No excess mortality after prostate biopsy: results from the European Randomized Study of Screening for Prostate Cancer.
Carlsson SV; Holmberg E; Moss SM; Roobol MJ; Schröder FH; Tammela TL; Aus G; Auvinen AP; Hugosson J
BJU Int; 2011 Jun; 107(12):1912-7. PubMed ID: 20950305
[TBL] [Abstract][Full Text] [Related]
8. Prostate cancer mortality in screen and clinically detected prostate cancer: estimating the screening benefit.
van Leeuwen PJ; Connolly D; Gavin A; Roobol MJ; Black A; Bangma CH; Schröder FH
Eur J Cancer; 2010 Jan; 46(2):377-83. PubMed ID: 19804966
[TBL] [Abstract][Full Text] [Related]
9. Prostate cancer mortality in the Finnish randomized screening trial.
Kilpeläinen TP; Tammela TL; Malila N; Hakama M; Santti H; Määttänen L; Stenman UH; Kujala P; Auvinen A
J Natl Cancer Inst; 2013 May; 105(10):719-25. PubMed ID: 23479454
[TBL] [Abstract][Full Text] [Related]
10. Outcomes of initially expectantly managed patients with low or intermediate risk screen-detected localized prostate cancer.
Bul M; van den Bergh RC; Zhu X; Rannikko A; Vasarainen H; Bangma CH; Schröder FH; Roobol MJ
BJU Int; 2012 Dec; 110(11):1672-7. PubMed ID: 22928973
[TBL] [Abstract][Full Text] [Related]
11. Impacts of a population-based prostate cancer screening programme on excess total mortality rates in men with prostate cancer: a randomized controlled trial.
van Leeuwen PJ; Kranse R; Hakulinen T; Hugosson J; Tammela TL; Ciattoy S; Roobol MJ; Zappa M; de Koning HJ; Bangma CH; Moss SM; Auvinen A; Schröder FH
J Med Screen; 2013 Mar; 20(1):33-8. PubMed ID: 23390203
[TBL] [Abstract][Full Text] [Related]
12. Effects of long-term exposure to traffic-related air pollution on respiratory and cardiovascular mortality in the Netherlands: the NLCS-AIR study.
Brunekreef B; Beelen R; Hoek G; Schouten L; Bausch-Goldbohm S; Fischer P; Armstrong B; Hughes E; Jerrett M; van den Brandt P
Res Rep Health Eff Inst; 2009 Mar; (139):5-71; discussion 73-89. PubMed ID: 19554969
[TBL] [Abstract][Full Text] [Related]
13. Pathological stage distribution in patients treated with radical prostatectomy reflecting the need for protocol-based active surveillance: results from a contemporary European patient cohort.
Seiler D; Randazzo M; Klotz L; Grobholz R; Baumgartner M; Isbarn H; Recker F; Kwiatkowski M
BJU Int; 2012 Jul; 110(2):195-200. PubMed ID: 22093744
[TBL] [Abstract][Full Text] [Related]
14. Cardiovascular comorbidity and treatment regret in men with recurrent prostate cancer.
Nguyen PL; Chen MH; Hoffman KE; Chen RC; Hu JC; Bennett CL; Kattan MW; Sartor O; Stein K; D'Amico AV
BJU Int; 2012 Jul; 110(2):201-5. PubMed ID: 22085233
[TBL] [Abstract][Full Text] [Related]
15. Comparison of screen detected and clinically diagnosed prostate cancer in the European randomized study of screening for prostate cancer, section rotterdam.
van der Cruijsen-Koeter IW; Vis AN; Roobol MJ; Wildhagen MF; de Koning HJ; van der Kwast TH; Schröder FH
J Urol; 2005 Jul; 174(1):121-5. PubMed ID: 15947595
[TBL] [Abstract][Full Text] [Related]
16. Global update on defining and treating high-risk localized prostate cancer with leuprorelin: a USA perspective--identifying men at diagnosis who are at high risk of prostate cancer death after surgery or radiation therapy.
D'Amico A
BJU Int; 2007 Jan; 99 Suppl 1():13-6; discussion 17-8. PubMed ID: 17229162
[TBL] [Abstract][Full Text] [Related]
17. Immediate risk of suicide and cardiovascular death after a prostate cancer diagnosis: cohort study in the United States.
Fang F; Keating NL; Mucci LA; Adami HO; Stampfer MJ; Valdimarsdóttir U; Fall K
J Natl Cancer Inst; 2010 Mar; 102(5):307-14. PubMed ID: 20124521
[TBL] [Abstract][Full Text] [Related]
18. High accuracy of Swedish death certificates in men participating in screening for prostate cancer: a comparative study of official death certificates with a cause of death committee using a standardized algorithm.
Godtman R; Holmberg E; Stranne J; Hugosson J
Scand J Urol Nephrol; 2011 Sep; 45(4):226-32. PubMed ID: 21463227
[TBL] [Abstract][Full Text] [Related]
19. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality.
Tsai HK; D'Amico AV; Sadetsky N; Chen MH; Carroll PR
J Natl Cancer Inst; 2007 Oct; 99(20):1516-24. PubMed ID: 17925537
[TBL] [Abstract][Full Text] [Related]
20. Selecting men diagnosed with prostate cancer for active surveillance using a risk calculator: a prospective impact study.
van Vugt HA; Roobol MJ; van der Poel HG; van Muilekom EH; Busstra M; Kil P; Oomens EH; Leliveld A; Bangma CH; Korfage I; Steyerberg EW
BJU Int; 2012 Jul; 110(2):180-7. PubMed ID: 22112199
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]